---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Dosage forms and strengths"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Dosage forms and strengths. Topics: Oral capsule, self-administered under monitoring; Doses studied in the phase 2b trial: 25 mg, 10 mg, and 1 mg; Dose evaluated for retreatment in phase 3: 25 mg; Capsule strength in investigator studies: 5 mg capsules given as five capsules. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Oral capsule, self-administered under monitoring

> “Patient self-administers oral capsule, monitored by a licensed HCP during session”
> “Orally administered formulation”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.2-2"></a>

### Doses studied in the phase 2b trial: 25 mg, 10 mg, and 1 mg

> “we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-2.1.2.2-3"></a>

### Dose evaluated for retreatment in phase 3: 25 mg

> “52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

<a id="topic-2.1.2.2-4"></a>

### Capsule strength in investigator studies: 5 mg capsules given as five capsules

> “The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

> “COMP360 psilocybin and placebo were administered as five capsules, matched for appearance, weight, color, texture and smell.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
